Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
NuPathe Inc.
ClinicalTrials.gov Identifier:
NCT00546650
First received: October 17, 2007
Last updated: April 25, 2012
Last verified: April 2012
  Purpose

The primary objective is to compare the pharmacokinetics (PK) of NP101 with the currently approved oral, injection and nasal spray formulations of Imitrex® in healthy volunteers and to assess the bioavailability relative to the 6 mg subcutaneous injection.

The secondary objective is to evaluate the safety of NP101 in healthy volunteers.


Condition Intervention Phase
Healthy
Drug: Sumatriptan succinate
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Single Center, Open Label, Randomized, Single-Dose, Five-Way Crossover Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by NuPathe Inc.:

Primary Outcome Measures:
  • Pharmacokinetics [ Time Frame: Blood samples to be drawn at pre-dose (within 15 minutes prior to dosing) and at 0.25, 0.50, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 16 hrs post dose. ] [ Designated as safety issue: No ]
    The primary objective was to compare the pharmacokinetics (PK) of NP101 (sumatriptan iontophoretic transdermal patch) with the currently approved oral, subcutaneous injection and nasal spray formulations of Imitrex® in healthy volunteers and to assess the bioavailability relative to the 6 mg subcutaneous injection.


Enrollment: 25
Study Start Date: November 2007
Study Completion Date: March 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
Drug: Sumatriptan succinate
NP101 iontophoretic transdermal system
Active Comparator: B
Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.
Drug: Sumatriptan succinate
oral, subcutaneous, and intranasal formulations
Active Comparator: C
Sumatriptan succinate (Imitrex®) injection: 6 mg subcutaneously (SQ).
Drug: Sumatriptan succinate
oral, subcutaneous, and intranasal formulations
Active Comparator: D
Sumatriptan (Imitrex®) nasal spray: 20 mg (one spray) intranasal (IN) into one nostril.
Drug: Sumatriptan succinate
oral, subcutaneous, and intranasal formulations
Experimental: E
NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
Drug: Sumatriptan succinate
NP101 iontophoretic transdermal system

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men or women aged 18 to 65 years.
  • Women of childbearing potential must be using a medically acceptable form of birth control for the duration of the study, and must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1 for all periods.
  • Subjects must have body mass index (BMI) of 18 to 30 kg/m2 inclusive.
  • Subjects must be able to communicate effectively with the study personnel.
  • Subjects must have, in the investigator's opinion, no clinically significant disease or abnormal laboratory values as determined by medical and psychiatric history, physical examination, or laboratory evaluations conducted at the screening visit or on clinic admission.
  • Subjects must have a 12-lead ECG without any clinically significant abnormalities of rate, rhythm, intervals or conduction, as determined by the investigator.
  • Subjects must be nonsmokers, defined as having not used any tobacco products in the 6 months before screening.
  • Subjects must have not consumed alcoholic beverages, poppy seeds, grapefruit, and/or grapefruit juice within 72 hours prior to admission to the clinic for Period 1 and for the duration of the study.
  • Subjects must be adequately informed of the nature and risks of the study and give written informed consent prior to screening.
  • The subject must be likely to complete the entire study.

Exclusion Criteria:

  • Female subjects who are pregnant or breast feeding or planning a pregnancy during the study.
  • A known hypersensitivity to sumatriptan or other triptan agents or the recipients of any of the formulations.
  • Subject currently has hypertension with blood pressure outside of normal range for age group.
  • Subject has hemiplegic or basilar migraine.
  • Subject has severe hepatic impairment.
  • Subject has any skin irritation or disease that might interfere with absorption of study drug or skin irritation assessment, including eczema, psoriasis, melanoma, or acne.
  • Subject has a tattoo that might interfere with skin erythema examination.
  • Subject has a positive test result for hepatitis B, or C or is known to be HIV positive or have a medical history of AIDS.
  • Subject who has been administered an injectable drug, except for local anesthetic or birth control, within 30 days prior to the initial study drug administration.
  • Subject who requires any medication on a regular basis.
  • Subject with a history of malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
  • Subject with a hemoglobin (Hgb) level of less than 7.5 mmol/L.
  • Subject has a history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes.
  • Recent (within one year of screening) history of alcohol abuse, illicit drug use, physical dependence to any opioid, or recent (within one year of screening) history of drug abuse or addiction.
  • Concurrent use of prescription (Rx) or over-the-counter (OTC) medications or natural medicine (herbal) products.
  • Subject is currently taking MAO-A inhibitors
  • Receipt of an investigational drug or participation in any clinical study within 90 days prior to study entry.
  • Donation of blood or blood products within 8 weeks prior to study entry.
  • Positive urine drug screen, including ethanol, cocaine, THC, barbiturates, amphetamines, benzodiazepines, and opiates.
  • Subject who is considered by the investigator or NuPathe, for any reason, to be an unsuitable candidate for receiving sumatriptan, or as being unsuitable for any other reason as judged by the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00546650

Locations
United States, Florida
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
Sponsors and Collaborators
NuPathe Inc.
Investigators
Principal Investigator: Thomas C Marbury, MD Orlando Clinical Research Center
  More Information

No publications provided

Responsible Party: NuPathe Inc.
ClinicalTrials.gov Identifier: NCT00546650     History of Changes
Other Study ID Numbers: NP101-005
Study First Received: October 17, 2007
Last Updated: April 25, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by NuPathe Inc.:
Focus of study is to compare pharmacokinetics

Additional relevant MeSH terms:
Sumatriptan
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 28, 2014